Joaquim Bosch-Barrera

Summary

Country: Spain

Publications

  1. ncbi Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient
    Joaquim Bosch-Barrera
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain
    Anticancer Res 34:4323-7. 2014
  2. ncbi Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain Girona Biomedical Research Institute IdIBGi, Girona, Spain Department of Medical Sciences, Medical School, University of Girona, Girona, Spain
    Anticancer Res 35:4871-5. 2015
  3. doi Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy
    Joaquim Bosch-Barrera
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain Electronic address
    Cancer Treat Rev 41:540-6. 2015
  4. doi Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain Department of Medical Sciences, Medical School, University of Girona, Girona, Spain Electronic address
    Lung Cancer 86:102-4. 2014
  5. doi Direct antitumour activity of zoledronic acid: preclinical and clinical data
    Joaquim Bosch-Barrera
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Clin Transl Oncol 13:148-55. 2011
  6. doi Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
    Clin Lung Cancer 12:335-40. 2011
  7. pmc Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
    Bruna Corominas-Faja
    Metabolism and Cancer Group Translational Research Laboratory Catalan Institute of Oncology Girona, Catalonia, Spain Girona Biomedical Research Institute IDIBGi Girona, Catalonia, Spain
    Cell Cycle 12:3390-404. 2013
  8. doi Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain
    Food Chem Toxicol 60:360-8. 2013
  9. doi Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:1235-46. 2012
  10. pmc Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2459. 2013

Collaborators

Detail Information

Publications20

  1. ncbi Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient
    Joaquim Bosch-Barrera
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain
    Anticancer Res 34:4323-7. 2014
    ..Silibinin exerts hepatoprotective, anti-inflammatory and anti-fibrotic effects. Several pre-clinical studies have shown anti-tumoral activity of silibinin in breast cancer cell lines...
  2. ncbi Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain Girona Biomedical Research Institute IdIBGi, Girona, Spain Department of Medical Sciences, Medical School, University of Girona, Girona, Spain
    Anticancer Res 35:4871-5. 2015
    ..To our knowledge, this is the first report of PD-L1 expression in CBPB. This could lead to new treatment options based on new immunotherapy agents blocking the PD-1/PD-L1 pathway for this rare disease with poor prognosis. ..
  3. doi Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy
    Joaquim Bosch-Barrera
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain Electronic address
    Cancer Treat Rev 41:540-6. 2015
    ..Finally, we review the ongoing clinical trials exploring the role of silibinin in cancer. ..
  4. doi Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain Department of Medical Sciences, Medical School, University of Girona, Girona, Spain Electronic address
    Lung Cancer 86:102-4. 2014
    ..Lung cancer is the most common solid tumor in critically ill cancer patients who are admitted to intensive care units (ICUs). An ICU trial consists of unlimited ICU support for a limited time period...
  5. doi Direct antitumour activity of zoledronic acid: preclinical and clinical data
    Joaquim Bosch-Barrera
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Clin Transl Oncol 13:148-55. 2011
    ..Translational questions regarding drug dose, dose interval, and sequence with chemotherapy treatment are also addressed...
  6. doi Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
    Clin Lung Cancer 12:335-40. 2011
    ..These considerations have been examined from the perspective of a national public healthcare system...
  7. pmc Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
    Bruna Corominas-Faja
    Metabolism and Cancer Group Translational Research Laboratory Catalan Institute of Oncology Girona, Catalonia, Spain Girona Biomedical Research Institute IDIBGi Girona, Catalonia, Spain
    Cell Cycle 12:3390-404. 2013
    ..Our findings highlight the benefit of administration of silibinin in combination with EGFR TKIs to target CSCs and minimize the ability of tumor cells to escape cell death in EGFR-mutant NSCLC patients...
  8. doi Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain
    Food Chem Toxicol 60:360-8. 2013
    ....
  9. doi Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:1235-46. 2012
    ....
  10. pmc Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2459. 2013
    ....
  11. pmc IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2560. 2013
    ....
  12. doi Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:865-70. 2012
    ..Restored antigenicity and immunogenicity of tumor cells may represent a previously unrecognized primary mode of action underlying the cancer-preventive effects of metformin...
  13. ncbi Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
    Elisabet Cuyàs
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
    Oncotarget 6:12279-96. 2015
    ....
  14. pmc Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 5:2344-8. 2014
    ..Perhaps then, the oncobiguanides, as we call them here, could be viewed as a mechanistically different type of anti-cancer drugs employed at doses notably higher than those used chronically when functioning as diabetobiguanides. ..
  15. pmc Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Oncotarget 3:395-8. 2012
    ....
  16. doi Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncol Rep 27:1887-92. 2012
    ....
  17. pmc Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells
    Bruna Corominas-Faja
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia Spain Girona Biomedical Research Institute IDIBGI, Girona, Catalonia Spain
    Oncotarget 5:8306-16. 2014
    ..Our findings reveal for the first time that ACACA may constitute a previously unrecognized target for novel anti-breast CSC therapies. ..
  18. pmc Metformin: multi-faceted protection against cancer
    Sonia del Barco
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 2:896-917. 2011
    ..Current and future clinical trials will elucidate whether metformin has the potential to be used in preventive and treatment settings as an adjuvant to current cancer therapeutics...
  19. ncbi [Teaching Bioethics to Students of Medicine with Problem-Based Learning (PBL)]
    Joaquim Bosch-Barrera
    Departamento de Ciencias Médicas, Facultad de Medicina, Universidad de Girona, Girona, España Departamento de Oncología Médica, Instituto Catalán de Oncología ICO Hospital Universitario Doctor Josep Trueta, Girona, Espana
    Cuad Bioet 26:303-9. 2015
    ..Students completed a course and faculty evaluation anonymously, which came out with positive results (median score of 8.5/10). ..
  20. doi The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience
    Joaquim Bosch-Barrera
    Department of Medical Oncology, Clinica Universidad de Navarra, 31008, Pamplona, Spain
    Clin Transl Oncol 14:835-41. 2012
    ..We present our institution's experience with the management of stage III (N2) NSCLC patients, analyzing whether the addition of surgery improves survival when compared with definitive CT-RT alone...